[144] Xeris Biopharma Holdings, Inc. SEC Filing
Xeris Biopharma Holdings, Inc. (XERS) submitted a Form 144 reporting a proposed sale of 42,500 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $309,225.75. The shares were acquired on 06/05/2024 by restricted stock vesting under a registered plan and the filing lists an approximate sale date of 08/12/2025.
The filing shows 161,480,367 shares outstanding, so the proposed sale is a very small portion of the company (approximately 0.026% of outstanding shares). The notice states there were no securities sold by the seller in the past three months and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. No earnings, financing, or management changes are disclosed in this filing.
Xeris Biopharma Holdings, Inc. (XERS) ha presentato un Form 144 segnalando la proposta di vendita di 42.500 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, per un valore di mercato complessivo di $309.225,75. Le azioni sono state acquisite il 06/05/2024 tramite il vesting di azioni soggette a restrizioni nell'ambito di un piano registrato e il deposito indica una data di vendita approssimativa del 08/12/2025.
Il filing mostra 161.480.367 azioni in circolazione, pertanto la vendita proposta rappresenta una quota minima della societ脿 (circa lo 0,026% delle azioni in circolazione). La comunicazione dichiara che il venditore non ha venduto titoli negli ultimi tre mesi e contiene la sua dichiarazione di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate sull'emittente. Nel documento non vengono riportati utili, operazioni di finanziamento o cambi nella direzione.
Xeris Biopharma Holdings, Inc. (XERS) present贸 un Form 144 notificando la propuesta de venta de 42.500 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en NASDAQ, por un valor de mercado agregado de $309.225,75. Las acciones fueron adquiridas el 06/05/2024 mediante el vesting de acciones restringidas en el marco de un plan registrado y la presentaci贸n indica una fecha aproximada de venta del 08/12/2025.
El documento muestra 161.480.367 acciones en circulaci贸n, por lo que la venta propuesta representa una porci贸n muy peque帽a de la compa帽铆a (aproximadamente el 0,026% de las acciones en circulaci贸n). La notificaci贸n se帽ala que el vendedor no ha vendido valores en los 煤ltimos tres meses e incluye la representaci贸n del vendedor de no tener conocimiento de informaci贸n material adversa no divulgada sobre el emisor. No se divulgan resultados, operaciones de financiaci贸n ni cambios en la direcci贸n en este filing.
Xeris Biopharma Holdings, Inc. (XERS)電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 齑濎暋 $309,225.75 攴滊鞚� 氤错喌欤� 42,500欤� 毵る弰毳� 鞝滌晥頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 霌彪霅� 頂岆灉鞐� 霐半ジ 鞝滍暅欤�(Restricted Stock) 氩犾姢韺呾溂搿� 06/05/2024鞐� 旆摑霅橃棃鞙茧┌, 鞝滌稖靹滌棎電� 雽�霝奠爜鞚� 毵る弰 鞓堨爼鞚检潉 08/12/2025搿� 響滌嫓頃橁碃 鞛堨姷雼堧嫟.
鞝滌稖靹滌棎 霐半ゴ氅� 鞙犿喌 欤检嫕靾橂姅 161,480,367欤茧, 鞝滌晥霅� 毵る弰電� 須岇偓 鞝勳泊鞚� 毵れ毎 鞛戩潃 牍勳(鞎� 0.026%)鞐� 頃措嫻頃╇媹雼�. 韱奠靹滌棎電� 韺愲Г鞛愱皜 斓滉芳 3臧滌洈 雮� 鞙犼皜歃濌秾鞚� 毵り皝頃� 氚� 鞐嗢潓鞚� 氚濏瀳瓿� 鞛堨溂氅�, 氚滍枆鞚胳棎 雽�頃� 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 韺愲Г鞛愱皜 歆勳垹頃橁碃 鞛堨姷雼堧嫟. 鞚� 鞝滌稖靹滌棎電� 鞁れ爜, 鞛愱笀臁半嫭 霕愲姅 瓴届榿歆� 氤�瓴届棎 甏�頃� 雮挫毄鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Xeris Biopharma Holdings, Inc. (XERS) a d茅pos茅 un Form 144 signalant la proposition de vente de 42 500 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur de march茅 totale de $309 225,75. Les actions ont 茅t茅 acquises le 06/05/2024 par le vesting d'actions restreintes dans le cadre d'un plan enregistr茅 et le d茅p么t indique une date de vente approximative au 08/12/2025.
Le d茅p么t indique 161 480 367 actions en circulation ; la vente propos茅e repr茅sente donc une part tr猫s faible de la soci茅t茅 (environ 0,026 % des actions en circulation). L'avis pr茅cise que le vendeur n'a pas c茅d茅 de titres au cours des trois derniers mois et inclut la d茅claration du vendeur selon laquelle il n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es concernant l'茅metteur. Aucun r茅sultat, financement ou changement de direction n'est divulgu茅 dans ce filing.
Xeris Biopharma Holdings, Inc. (XERS) hat ein Form 144 eingereicht, in dem ein geplanter Verkauf von 42.500 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $309.225,75 gemeldet wird. Die Aktien wurden am 06/05/2024 durch das Vesting von Restricted Stock im Rahmen eines registrierten Plans erworben, und in der Meldung ist ein ungef盲hres Verkaufsdatum von 08/12/2025 angegeben.
Die Einreichung weist 161.480.367 ausstehende Aktien aus, daher stellt der vorgeschlagene Verkauf einen sehr kleinen Anteil des Unternehmens dar (etwa 0,026% der ausstehenden Aktien). Die Mitteilung besagt, dass der Verk盲ufer in den letzten drei Monaten keine Wertpapiere verkauft hat, und enth盲lt die Erkl盲rung des Verk盲ufers, ihm seien keine nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten bekannt. In diesem Filing werden keine Ergebnisse, Finanzierungen oder F眉hrungs盲nderungen offengelegt.
- Planned sale quantified: 42,500 common shares with an aggregate market value of $309,225.75
- Acquisition method disclosed: shares were acquired by restricted stock vesting under a registered plan on 06/05/2024
- Compliance disclosure present: sale to be executed through Morgan Stanley Smith Barney LLC and seller attests to no undisclosed material adverse information
- None.
Insights
TL;DR: Small, routine Form 144 filing for an insider sale; unlikely to move markets.
The filing documents a proposed sale of 42,500 common shares valued at $309,225.75 via Morgan Stanley Smith Barney LLC, representing roughly 0.026% of 161,480,367 outstanding shares. That scale suggests the transaction is immaterial to company capitalization and unlikely to signal a change in corporate fundamentals. The shares were issued via restricted stock vesting on 06/05/2024 and no other sales in the past three months are reported, indicating this is an isolated planned disposition rather than part of a larger, ongoing sell-down.
TL;DR: Filing meets disclosure expectations; no governance red flags visible from this notice.
The Form 144 lists the broker, nature of acquisition (restricted stock vesting), and seller representation regarding material information, aligning with standard compliance for Rule 144 dispositions. There is no indication of undisclosed related-party transactions, unusual timing, or aggregated sales over the prior three months. Absent additional context or concurrent filings, this notice appears to be a routine compliance disclosure rather than a governance concern.
Xeris Biopharma Holdings, Inc. (XERS) ha presentato un Form 144 segnalando la proposta di vendita di 42.500 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, per un valore di mercato complessivo di $309.225,75. Le azioni sono state acquisite il 06/05/2024 tramite il vesting di azioni soggette a restrizioni nell'ambito di un piano registrato e il deposito indica una data di vendita approssimativa del 08/12/2025.
Il filing mostra 161.480.367 azioni in circolazione, pertanto la vendita proposta rappresenta una quota minima della societ脿 (circa lo 0,026% delle azioni in circolazione). La comunicazione dichiara che il venditore non ha venduto titoli negli ultimi tre mesi e contiene la sua dichiarazione di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate sull'emittente. Nel documento non vengono riportati utili, operazioni di finanziamento o cambi nella direzione.
Xeris Biopharma Holdings, Inc. (XERS) present贸 un Form 144 notificando la propuesta de venta de 42.500 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en NASDAQ, por un valor de mercado agregado de $309.225,75. Las acciones fueron adquiridas el 06/05/2024 mediante el vesting de acciones restringidas en el marco de un plan registrado y la presentaci贸n indica una fecha aproximada de venta del 08/12/2025.
El documento muestra 161.480.367 acciones en circulaci贸n, por lo que la venta propuesta representa una porci贸n muy peque帽a de la compa帽铆a (aproximadamente el 0,026% de las acciones en circulaci贸n). La notificaci贸n se帽ala que el vendedor no ha vendido valores en los 煤ltimos tres meses e incluye la representaci贸n del vendedor de no tener conocimiento de informaci贸n material adversa no divulgada sobre el emisor. No se divulgan resultados, operaciones de financiaci贸n ni cambios en la direcci贸n en este filing.
Xeris Biopharma Holdings, Inc. (XERS)電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 齑濎暋 $309,225.75 攴滊鞚� 氤错喌欤� 42,500欤� 毵る弰毳� 鞝滌晥頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 霌彪霅� 頂岆灉鞐� 霐半ジ 鞝滍暅欤�(Restricted Stock) 氩犾姢韺呾溂搿� 06/05/2024鞐� 旆摑霅橃棃鞙茧┌, 鞝滌稖靹滌棎電� 雽�霝奠爜鞚� 毵る弰 鞓堨爼鞚检潉 08/12/2025搿� 響滌嫓頃橁碃 鞛堨姷雼堧嫟.
鞝滌稖靹滌棎 霐半ゴ氅� 鞙犿喌 欤检嫕靾橂姅 161,480,367欤茧, 鞝滌晥霅� 毵る弰電� 須岇偓 鞝勳泊鞚� 毵れ毎 鞛戩潃 牍勳(鞎� 0.026%)鞐� 頃措嫻頃╇媹雼�. 韱奠靹滌棎電� 韺愲Г鞛愱皜 斓滉芳 3臧滌洈 雮� 鞙犼皜歃濌秾鞚� 毵り皝頃� 氚� 鞐嗢潓鞚� 氚濏瀳瓿� 鞛堨溂氅�, 氚滍枆鞚胳棎 雽�頃� 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 韺愲Г鞛愱皜 歆勳垹頃橁碃 鞛堨姷雼堧嫟. 鞚� 鞝滌稖靹滌棎電� 鞁れ爜, 鞛愱笀臁半嫭 霕愲姅 瓴届榿歆� 氤�瓴届棎 甏�頃� 雮挫毄鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Xeris Biopharma Holdings, Inc. (XERS) a d茅pos茅 un Form 144 signalant la proposition de vente de 42 500 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur de march茅 totale de $309 225,75. Les actions ont 茅t茅 acquises le 06/05/2024 par le vesting d'actions restreintes dans le cadre d'un plan enregistr茅 et le d茅p么t indique une date de vente approximative au 08/12/2025.
Le d茅p么t indique 161 480 367 actions en circulation ; la vente propos茅e repr茅sente donc une part tr猫s faible de la soci茅t茅 (environ 0,026 % des actions en circulation). L'avis pr茅cise que le vendeur n'a pas c茅d茅 de titres au cours des trois derniers mois et inclut la d茅claration du vendeur selon laquelle il n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es concernant l'茅metteur. Aucun r茅sultat, financement ou changement de direction n'est divulgu茅 dans ce filing.
Xeris Biopharma Holdings, Inc. (XERS) hat ein Form 144 eingereicht, in dem ein geplanter Verkauf von 42.500 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $309.225,75 gemeldet wird. Die Aktien wurden am 06/05/2024 durch das Vesting von Restricted Stock im Rahmen eines registrierten Plans erworben, und in der Meldung ist ein ungef盲hres Verkaufsdatum von 08/12/2025 angegeben.
Die Einreichung weist 161.480.367 ausstehende Aktien aus, daher stellt der vorgeschlagene Verkauf einen sehr kleinen Anteil des Unternehmens dar (etwa 0,026% der ausstehenden Aktien). Die Mitteilung besagt, dass der Verk盲ufer in den letzten drei Monaten keine Wertpapiere verkauft hat, und enth盲lt die Erkl盲rung des Verk盲ufers, ihm seien keine nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten bekannt. In diesem Filing werden keine Ergebnisse, Finanzierungen oder F眉hrungs盲nderungen offengelegt.
FAQ
What did Xeris Biopharma (XERS) report on Form 144?
When were the shares being sold by the XERS filer acquired?
What is the expected sale date listed in the XERS Form 144?
How large is the proposed sale relative to Xeris' outstanding shares?
Were there any securities sold by the filer in the past three months?
